Skip to search formSkip to main contentSkip to account menu

Recentin

National Institutes of Health

Related topics

Related topics

1 relation
AZD2171

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors
Abstract Literature data on the clinical pharmacokinetics of various VEGFR-2 inhibitors along with in vitro potency data were… 
2011
2011
A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics
BackgroundCediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the… 
2010
2010
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
2010
2010
Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo
Cediranib (RECENTIN™) is a highly potent vascular endothelial growth factor (VEGF) signaling inhibitor of all three VEGF… 
2010
2010
Abstract 376: Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)
Emergence of therapeutic resistance to angiogenesis inhibitors, the mechanisms of which are poorly understood, remains a major… 
2009
2009
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
2009
2009
Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.
Background: Cediranib (RECENTIN™) is a highly potent VEGF signaling inhibitor that has shown clinical activity across a range of… 
2008
2008
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
A number of pre-clinical studies have suggested that blocking vascular endothelial growth factor (VEGF) signalling can be… 
2007
2007
Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer
B263 Background: Cediranib is a highly selective and potent oral tyrosine kinase inhibitor (TKI) of VEGFR1, VEGFR2, c-Kit, and… 
2005
2005
The structure of human S-phase chromosome fibres
Recentin situ hybridization studies suggested that within the range of 0.1–1.0 Mb, human interphase chromosomes follow a random… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)